What is the 13F Pro Quality Score for UTHR?

13F Pro ranks UNITED THERAPEUTICS Corp (UTHR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View UTHR's current score at https://13fpro.ai/company/UTHR (free sign-up required for the full ranking).

Where does 13F Pro source UTHR data?

All UNITED THERAPEUTICS Corp fundamentals and ownership data come directly from SEC EDGAR. UNITED THERAPEUTICS Corp files with the SEC under CIK 1082554. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is UTHR in?

UNITED THERAPEUTICS Corp (UTHR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives UTHR's revenue?

Per UNITED THERAPEUTICS Corp's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Tyvaso DPI ($326.6M, +4% YoY); Nebulized Tyvaso ($126.0M, -18% YoY); Remodulin ($126.3M, -6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/UTHR.

What are UTHR's largest expenses?

UNITED THERAPEUTICS Corp's latest 10-Q reports these as the largest expense items: Selling, general, and administrative ($206.7M, -3% YoY); Research and development ($146.3M, +9% YoY); Cost of sales ($99.5M, +14% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is UTHR research updated on 13F Pro?

UTHR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

UNITED THERAPEUTICS Corp(UTHR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1082554 UTHR stock profile & AI dashboard →

13F Pro Quality Score

71.3/100

Rank #189 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

60.0/100

Profitability

96.4/100

Balance Sheet

94.7/100

Earnings Quality

69.4/100

Free Cash Flow

87.6/100

Institutional Flow

9.9/100

Revenue Scale

70.6/100

Dilution Risk

25.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why UTHR Scores 71/100

exact factor attribution · 2026-09-11

UTHR's composite is driven by profitability and free cash flow, held back by institutional flow and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.0 pts

96th pct

Free cash flow

+5.6 pts

88th pct

Capital efficiency

+4.5 pts

95th pct

Scale

+3.1 pts

71th pct

Revenue growth

+2.0 pts

60th pct

Earnings quality

+1.9 pts

69th pct

Earnings growth

+0.4 pts

57th pct

Shareholder dilution

-1.2 pts

26th pct

Institutional flow

-2.0 pts

10th pct

Latest change (2026-08-05): 80 → 76 · ↓ Revenue growth 75→51

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

UTHR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for UNITED THERAPEUTICS Corp (UTHR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UTHR at 71.3/100 on a 32-signal composite quality model, placing it at rank #189 of 2,961 stocks — the top 10% of the AI-ranked universe. UTHR scores in the top quartile across profitability (96.4), balance sheet strength (94.7), free cash flow (87.6). Areas of concern include institutional flow (9.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), UNITED THERAPEUTICS Corp reports quarterly revenue of $783.3M, net income of $333.0M, an operating margin of 42.2%. Top institutional holders of UTHR by reported 13-F value include BlackRock, Avoro Capital Advisors, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. UTHR trades on the Nasdaq exchange and files with the SEC under CIK 1082554. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UTHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UNITED THERAPEUTICS Corp directly from SEC EDGAR. UNITED THERAPEUTICS Corp's 13F Pro composite quality score has ranged between 65 and 86 since 2021, currently 71.3 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about UNITED THERAPEUTICS Corp

Quirks, history, and lore behind UTHR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
Annual revenue of roughly $2 billion, yet it runs with an unusually small headcount for its size — a lean machine that prints serious margins by focusing on a single disease area.
3
The History
Founded in the late 1990s, the company was built from the ground up around one devastating condition — pulmonary arterial hypertension — by a founder with a deeply personal reason to cure it.
4
The Secret
Its founder and CEO is a transgender pioneer and futurist who also runs a separate company dedicated to xenotransplantation — growing human-compatible organs in pigs.
5
The Lore
The company's PAH drug franchise — including Remodulin and Tyvaso — dominates its niche, and it has invested heavily in 3D-printed lungs and regenerative medicine as its next frontier.
6
The Giveaway
CEO Martine Rothblatt founded it after her daughter was diagnosed with PAH — the company's ticker is UTHR and its name pairs a certain global adjective with the word for healing.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving UTHR's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from UNITED THERAPEUTICS Corp's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues fell 2% YoY to $783.3M as an 18% decline in Nebulized Tyvaso sales from competitive pressure offset 4% growth in Tyvaso DPI, while operating income dropped to $330.8M from $364.5M.

Biggest Revenue Drivers

Tyvaso DPI$326.6M+4% YoY

Increase in quantities sold of $6.9M and a price increase of $9.4M, partially offset by higher gross-to-net deductions

Nebulized Tyvaso$126.0M-18% YoY

Decrease in U.S. quantities sold of $37.6M, partially offset by a price increase; availability of competitive therapies negatively impacted sales

Biggest Revenue Drivers

Total revenue: $783.3M-2% YoY

Tyvaso DPI$326.6M+4% YoY

Increase in quantities sold of $6.9M and a price increase of $9.4M, partially offset by higher gross-to-net deductions

Nebulized Tyvaso$126.0M-18% YoY

Decrease in U.S. quantities sold of $37.6M, partially offset by a price increase; availability of competitive therapies negatively impacted sales

Remodulin$126.3M-6% YoY

Decrease in U.S. quantities sold of $12.3M, partially offset by an increase in international net product sales

Orenitram$125.7M+1% YoY

Growth in quantities sold

Unituxin$65.2M+12% YoY

Largest Expense Items

Selling, general, and administrative$206.7M-3% YoY

Decrease driven by absence of a $21.7M PP&E impairment recorded in the prior-year quarter, partially offset by higher personnel, consulting, and sales & marketing costs

Research and development$146.3M+9% YoY

Increase in expenditures related to cardiopulmonary treatment projects and an increase in the fair value of contingent consideration obligations for organ/organ-alternative projects

Cost of sales$99.5M+14% YoY

Increase in inventory reserve expense, including $7.5M of estimated losses related to a Tyvaso DPI commercial supply agreement

Margins: Operating income fell to $330.8M from $364.5M YoY as revenue declined 2% while cost of sales and R&D expense both rose; SG&A declined only because the prior-year quarter included a one-time $21.7M PP&E impairment that did not recur.

Watch Items from the Filing

Two U.S. distributors accounted for 48% and 37% of total revenues in Q2 FY2026 (85% combined), creating concentrated counterparty exposure.
Sandoz litigation: accrued liability of $75.7M (damages, prejudgment and post-judgment interest through June 30, 2026) with appeal pending before the Third Circuit; adverse outcome could exceed the accrual.
Nebulized Tyvaso and Remodulin sales declined YoY, which the filing attributes to competition from newly launched therapies including Liquidia's Yutrepia and Merck's Winrevair.
$2.0B share repurchase program authorized in March 2026; $1.5B already executed via ASR agreements with $500M remaining available through March 2027.
Subsequent to quarter-end, acquired Thymmune Therapeutics for ~$140M upfront (expensed in Q3 2026 as IPR&D) plus up to $160M in contingent milestone payments.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$783.3M

Net Income

Q2 2026

$333.0M

Free Cash Flow

Q2 2026

$205.6M

Operating Margin

Q2 2026

42.2%

ROIC

Q2 2026

20.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.6% YoY

$3.18BFY 2025

FY22 $1.94BFY23 $2.33BFY24 $2.88BFY25 $3.18B

Net Income

+11.7% YoY

$1.33BFY 2025

FY22 $727.3MFY23 $984.8MFY24 $1.20BFY25 $1.33B

Operating Income

+8.4% YoY

$1.49BFY 2025

FY22 $979.7MFY23 $1.18BFY24 $1.38BFY25 $1.49B

EPS (Diluted)

+13.1% YoY

$27.86FY 2025

FY22 $15.00FY23 $19.81FY24 $24.64FY25 $27.86

Total Assets

+7.0% YoY

$7.88BFY 2025

FY22 $6.04BFY23 $7.17BFY24 $7.36BFY25 $7.88B

Op. Cash Flow

+17.6% YoY

$1.56BFY 2025

FY22 $802.5MFY23 $978.0MFY24 $1.33BFY25 $1.56B

Free Cash Flow

-3.7% YoY

$1.04BFY 2025

FY22 $663.7MFY23 $747.6MFY24 $1.08BFY25 $1.04B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.18B +10.6%	$2.88B +23.6%	$2.33B +20.2%	$1.94B +14.9%	$1.69B +13.6%	$1.48B
Net Income	$1.33B +11.7%	$1.20B +21.4%	$984.8M +35.4%	$727.3M +52.9%	$475.8M	—
Operating Income	$1.49B +8.4%	$1.38B +16.2%	$1.18B +20.9%	$979.7M +76.2%	$555.9M -6.4%	$593.6M
EPS (Diluted)	$27.86 +13.1%	$24.64 +24.4%	$19.81 +32.1%	$15.00 +49.1%	$10.06 -12.8%	$11.54
Total Assets	$7.88B +7.0%	$7.36B +2.7%	$7.17B +18.6%	$6.04B +16.9%	$5.17B +12.0%	$4.62B
Operating Cash Flow	$1.56B +17.6%	$1.33B +35.7%	$978.0M +21.9%	$802.5M +34.2%	$598.2M -20.8%	$755.7M
Free Cash Flow	$1.04B -3.7%	$1.08B +44.5%	$747.6M +12.6%	$663.7M +39.0%	$477.4M -31.4%	$696.4M

Get alerted when UTHR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for UNITED THERAPEUTICS Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of UTHR

BlackRock, Inc.
$2.9B5,294,529 sh
Avoro Capital Advisors LLC
$1.5B2,777,777 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.0B1,919,429 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0B1,918,256 sh
STATE STREET CORP
$1.0B1,898,064 sh
RENAISSANCE TECHNOLOGIES LLC
$925.8M1,708,739 sh
WELLINGTON MANAGEMENT GROUP LLP
$747.2M1,379,025 sh
GEODE CAPITAL MANAGEMENT, LLC
$538.9M996,598 sh
Jupiter Topco LLC
$450.1M831,129 sh
NORGES BANK
$376.4M694,753 sh

Fund	Value	Shares
BlackRock, Inc.	$2.9B	5,294,529
Avoro Capital Advisors LLC	$1.5B	2,777,777
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.0B	1,919,429
VANGUARD CAPITAL MANAGEMENT LLC	$1.0B	1,918,256
STATE STREET CORP	$1.0B	1,898,064
RENAISSANCE TECHNOLOGIES LLC	$925.8M	1,708,739
WELLINGTON MANAGEMENT GROUP LLP	$747.2M	1,379,025
GEODE CAPITAL MANAGEMENT, LLC	$538.9M	996,598
Jupiter Topco LLC	$450.1M	831,129
NORGES BANK	$376.4M	694,753

Companies Similar to UTHR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

EXEL

EXELIXIS, INC.

AI score

Very similar · 29 shared holders

LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Very similar · 37 shared holders

Vestal Point Capital, LP Swedbank AB CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

INCY

INCYTE CORP

AI score

Very similar · 36 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC LSV ASSET MANAGEMENT Robeco Institutional Asset Management B.V.

JAZZ

Jazz Pharmaceuticals plc

AI score

Very similar · 26 shared holders

Swedbank AB LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.

REGN

REGENERON PHARMACEUTICALS, INC.

AI score

Shared smart-money ownership · 34 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC LSV ASSET MANAGEMENT Swedbank AB

ALNY

ALNYLAM PHARMACEUTICALS, INC.

AI score

Shared smart-money ownership · 27 shared holders

BAILLIE GIFFORD & CO Deep Track Capital, LP Robeco Institutional Asset Management B.V.

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Similar quality profile · 28 shared holders

Swedbank AB BAILLIE GIFFORD & CO Bellevue Group AG

BIIB

BIOGEN INC.

AI score

Shared smart-money ownership · 28 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC LSV ASSET MANAGEMENT Swedbank AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put UTHR on your watchlist

Track score changes the day UNITED THERAPEUTICS Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is UTHR a good stock to buy?

13F Pro's AI-powered analysis of UNITED THERAPEUTICS Corp (UTHR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UTHR are available on the UTHR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. UTHR is classified as a large company.

Which hedge funds own UTHR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UTHR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UNITED THERAPEUTICS Corp's investment landscape.